Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Trivalent Inactivated Influenza Vaccine in Healthy Adults
NCT00006146Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2000
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of trivalent inactivated influenza vaccine in influenza (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Immune response to vaccine at 21 days. Started Aug 2000; status: completed.
02
Drugs
trivalent inactivated influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00006146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006146.